Literature DB >> 27214079

Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation.

I Petruskevicius1, M Ludvigsen2, R Hjortebjerg3, B S Sørensen4, P Kamper1, M Vase1, L G Oestgaard1, B Nielsen1, B Honoré2, M Bjerre3, G A Rabinovich5, F A d'Amore1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27214079     DOI： 10.1038/bmt.2016.127

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death.

Authors:  Marta A Toscano; Germán A Bianco; Juan M Ilarregui; Diego O Croci; Jorge Correale; Joseph D Hernandez; Norberto W Zwirner; Francoise Poirier; Eleanor M Riley; Linda G Baum; Gabriel A Rabinovich
Journal:  Nat Immunol       Date:  2007-06-24       Impact factor: 25.606

Review 2.  Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

Authors:  Y P L Linhares; S Pavletic; R P Gale
Journal:  Bone Marrow Transplant       Date:  2012-05-14       Impact factor: 5.483

3.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

Authors:  P Ljungman; M Bregni; M Brune; J Cornelissen; T de Witte; G Dini; H Einsele; H B Gaspar; A Gratwohl; J Passweg; C Peters; V Rocha; R Saccardi; H Schouten; A Sureda; A Tichelli; A Velardi; D Niederwieser
Journal:  Bone Marrow Transplant       Date:  2009-07-06       Impact factor: 5.483

Review 4.  Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer.

Authors:  Gabriel A Rabinovich; Diego O Croci
Journal:  Immunity       Date:  2012-03-23       Impact factor: 31.745

5.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Georg N Franke; Ginna G Laport; Thomas R Chauncey; Edward Agura; Richard T Maziarz; Amelia Langston; Parameswaran Hari; Michael A Pulsipher; Wolfgang Bethge; Firoozeh Sahebi; Benedetto Bruno; Michael B Maris; Andrew Yeager; Finn Bo Petersen; Lars Vindeløv; Peter A McSweeney; Kai Hübel; Marco Mielcarek; George E Georges; Dietger Niederwieser; Karl G Blume; David G Maloney; Rainer Storb
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272

Review 6.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

7.  Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease.

Authors:  G E Krassas; N Pontikides; T Kaltsas; A Dumas; J Frystyk; J W Chen; A Flyvbjerg
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

Review 8.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

Review 9.  Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation.

Authors:  Gabriel A Rabinovich; Marta A Toscano
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

10.  Amelioration of graft versus host disease by galectin-1.

Authors:  Linda G Baum; Douglas P Blackall; Sarah Arias-Magallano; Danielle Nanigian; Soo Y Uh; Jordan M Browne; Douglas Hoffmann; Christos E Emmanouilides; Mary C Territo; Gayle Cocita Baldwin
Journal:  Clin Immunol       Date:  2003-12       Impact factor: 3.969
View more
  1 in total

1.  Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation.

Authors:  Morten Nørgaard Andersen; Maja Ludvigsen; Niels Abildgaard; Irma Petruskevicius; Rikke Hjortebjerg; Mette Bjerre; Bent Honoré; Holger J Møller; Niels F Andersen
Journal:  Onco Targets Ther       Date:  2017-04-04       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.